--- title: "Hong Kong stock movement: DIAGENS-B rises 11.76% as funds become active and volatility increases, reason for the movement pending clarification" type: "News" locale: "en" url: "https://longbridge.com/en/news/297269280.md" description: "DIAGENS-B rose 11.76%; MicroPort Scientific Corporation-B fell 4.80%, with a transaction volume of HKD 106 million; Tianxing Medical fell 5.74%, with a transaction volume of HKD 31.24 million; MicroPort Medical fell 1.35%, with a transaction volume of HKD 30.21 million; True Health Medical-B fell 8.40%, with a market value of HKD 22 billion" datetime: "2026-08-28T05:27:01.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/297269280.md) - [en](https://longbridge.com/en/news/297269280.md) - [zh-HK](https://longbridge.com/zh-HK/news/297269280.md) generator: "portal-rs" --- # Hong Kong stock movement: DIAGENS-B rises 11.76% as funds become active and volatility increases, reason for the movement pending clarification **Hong Kong Stock Movement** DIAGENS-B, up 11.76%, with no significant news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. **Stocks with High Trading Volume in the Industry** MicroPort Scientific-B down 4.80%. Based on recent key news: 1. On August 27, MicroPort Scientific-B announced the establishment of an Environmental, Social, and Governance Committee to strengthen the company's governance structure. This move may attract market attention to the company's future development direction, leading to stock price fluctuations. 2. On August 27, the company announced changes in the board of directors, with Liu Yu and Liang Min resigning and new directors being nominated. This personnel change may raise market concerns about the stability of the company's management, affecting the stock price. 3. On August 27, the company postponed the board meeting to August 31, which will review the interim results and possible interim dividends. The postponement may increase market uncertainty regarding the company's financial situation, affecting the stock price. The medical technology industry has been volatile recently and requires attention. Tianxing Medical, down 5.74%, with a trading volume of HKD 31.24 million, and no significant news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. MicroPort Medical down 1.35%. Based on recent key news: 1. On August 27, MicroPort Medical announced the half-year performance of its 40.32%-owned subsidiary, HeartCare Medical Technology, with revenue growth of 11.1% and net profit growth of 2.5%. Despite the performance growth, market concerns about its profitability may lead to a decline in stock price. 2. On August 26, Zhitong Finance reported that HeartCare Medical Technology's net profit increased by 2.45% year-on-year, but R&D expenses grew by 42.37%, which may raise investor concerns about rising costs, affecting the stock price. 3. On August 27, MicroPort Medical released its performance report through the Hong Kong Stock Exchange disclosure system, emphasizing revenue and net profit growth, but failed to alleviate market concerns about future profitability, leading to stock price fluctuations. The overall industry performance is stable, with significant capital inflow. **Stocks with High Market Capitalization in the Industry** Zhenjiankang Medical-B down 8.40%. Based on recent key news: 1. On August 25, Zhenjiankang Medical-B signed a strategic cooperation framework agreement with General Technology Liaoning Pharmaceutical Co., Ltd., aiming to promote the standardized implementation of tumor minimally invasive intervention technology in the three northeastern provinces. This cooperation is expected to enhance the company's market influence, but the market reaction has been poor in the short term, leading to a decline in stock price. 2. On August 26, Zhenjiankang Medical-B obtained compliant procurement channels for public hospitals in Liaoning Province through cooperation with state-owned enterprises, further expanding its layout in the northeastern market. However, the market remains cautious about the long-term benefits of the cooperation, putting pressure on the stock price. 3. On August 25, Zhenjiankang Medical-B announced that several of its self-developed products have received Class III medical device registration certificates from the National Medical Products Administration, demonstrating the company's leading position in the field of tumor minimally invasive surgical robots. However, the market still has doubts about its short-term profitability, affecting stock price performance The competition in the healthcare industry is fierce, and the impact of policies is significant ### Related Stocks - [02526.HK](https://longbridge.com/en/quote/02526.HK.md) - [02252.HK](https://longbridge.com/en/quote/02252.HK.md) - [01609.HK](https://longbridge.com/en/quote/01609.HK.md) - [00853.HK](https://longbridge.com/en/quote/00853.HK.md) - [02697.HK](https://longbridge.com/en/quote/02697.HK.md) ## Related News & Research - [Chinese medical AI model wins top state science award as sectoral "ChatGPT moment" arrives ](https://longbridge.com/en/news/303676488.md) - [Hangzhou Diagens Grants 778,962 Share Awards to 23 Employees](https://longbridge.com/en/news/302434575.md) - [Li Auto October deliveries fall to 29,025, lowest since February](https://longbridge.com/en/news/303843656.md) - [Xiaomi Auto delivers over 50,000 vehicles in October as Sky Nomad drives return to year-on-year growth](https://longbridge.com/en/news/303843080.md) - [EMCD Coinhold Wallet Sees Growing Demand in Latin America and Africa Amid Rising Crypto Adoption](https://longbridge.com/en/news/303829926.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**